Profile - To The Moon

Kenny52041

Posts · 38Posts · 38
Following · 0Following · 0
Followers · 0Followers · 0

- Kenny52041Kenny52041
  ·2021-08-02
  ?
  Sorry, this post has been deleted
  1.96K Comment
  2
  Share
  Report
- Kenny52041Kenny52041
  ·2021-07-18
  nice
  Sorry, this post has been deleted
  1.69K Comment
  5
  Share
  Report
- Kenny52041Kenny52041
  ·2021-07-09
  power~~
  辉瑞研发新冠疫苗增强剂，以应对德尔塔变异病毒
  辉瑞及其合作伙伴BioNTech周四宣布，他们正开发一种针对“德尔塔”变种病毒的新冠疫苗增强剂，因为人们越来越担心这种高度传染性的毒株已经成为美国新冠病毒的主要毒株。两家公司表示，尽管他们认为目前的
  辉瑞研发新冠疫苗增强剂，以应对德尔塔变异病毒
  2.55K Comment
  1
  Share
  Report
- Kenny52041Kenny52041
  ·2021-06-25
  power~~~~
  Sorry, this post has been deleted
  2.33K Comment
  Like
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586333932625551","uuid":"3586333932625551","gmtCreate":1623239930102,"gmtModify":1623239930102,"name":"Kenny52041","pinyin":"kenny52041","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":224,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":805955920,"gmtCreate":1627856363560,"gmtModify":1703496477509,"author":{"id":"3586333932625551","authorId":"3586333932625551","name":"Kenny52041","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586333932625551","idStr":"3586333932625551"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805955920","repostId":"1198503623","repostType":4,"isVote":1,"tweetType":1,"viewCount":1958,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179592224,"gmtCreate":1626558906968,"gmtModify":1703761625763,"author":{"id":"3586333932625551","authorId":"3586333932625551","name":"Kenny52041","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586333932625551","idStr":"3586333932625551"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/179592224","repostId":"1169032103","repostType":4,"isVote":1,"tweetType":1,"viewCount":1692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143868953,"gmtCreate":1625788064072,"gmtModify":1703748438965,"author":{"id":"3586333932625551","authorId":"3586333932625551","name":"Kenny52041","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586333932625551","idStr":"3586333932625551"},"themes":[],"htmlText":"power~~","listText":"power~~","text":"power~~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143868953","repostId":"1106457456","repostType":4,"repost":{"id":"1106457456","kind":"news","pubTimestamp":1625786090,"share":"https://ttm.financial/m/news/1106457456?lang=&edition=fundamental","pubTime":"2021-07-09 07:14","market":"us","language":"zh","title":"辉瑞研发新冠疫苗增强剂，以应对德尔塔变异病毒","url":"https://stock-news.laohu8.com/highlight/detail?id=1106457456","media":"新浪财经","summary":"辉瑞及其合作伙伴BioNTech周四宣布，他们正开发一种针对“德尔塔”变种病毒的新冠疫苗增强剂，因为人们越来越担心这种高度传染性的毒株已经成为美国新冠病毒的主要毒株。\n两家公司表示，尽管他们认为目前的","content":"<p><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>及其合作伙伴BioNTech周四宣布，他们正开发一种针对“德尔塔”变种病毒的新冠疫苗增强剂，因为人们越来越担心这种高度传染性的毒株已经成为美国新冠病毒的主要毒株。</p>\n<p>两家公司表示，尽管他们认为目前的两剂疫苗如果施打第三剂有可能对包括德尔塔在内的所有已知变种保持“最高水平”的保护，但他们仍在“保持警惕”，并正在开发一种更新版本的疫苗。</p>\n<p>两家公司表示，临床研究最早可能于8月开始，但需获得监管机构的批准。</p>","source":"XLCJ","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞研发新冠疫苗增强剂，以应对德尔塔变异病毒</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞研发新冠疫苗增强剂，以应对德尔塔变异病毒\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 07:14 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-07-09/doc-ikqcfnca5780249.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>辉瑞及其合作伙伴BioNTech周四宣布，他们正开发一种针对“德尔塔”变种病毒的新冠疫苗增强剂，因为人们越来越担心这种高度传染性的毒株已经成为美国新冠病毒的主要毒株。\n两家公司表示，尽管他们认为目前的两剂疫苗如果施打第三剂有可能对包括德尔塔在内的所有已知变种保持“最高水平”的保护，但他们仍在“保持警惕”，并正在开发一种更新版本的疫苗。\n两家公司表示，临床研究最早可能于8月开始，但需获得监管机构的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-07-09/doc-ikqcfnca5780249.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f78fc8716e758c96a05271f4a9570166","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-07-09/doc-ikqcfnca5780249.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106457456","content_text":"辉瑞及其合作伙伴BioNTech周四宣布，他们正开发一种针对“德尔塔”变种病毒的新冠疫苗增强剂，因为人们越来越担心这种高度传染性的毒株已经成为美国新冠病毒的主要毒株。\n两家公司表示，尽管他们认为目前的两剂疫苗如果施打第三剂有可能对包括德尔塔在内的所有已知变种保持“最高水平”的保护，但他们仍在“保持警惕”，并正在开发一种更新版本的疫苗。\n两家公司表示，临床研究最早可能于8月开始，但需获得监管机构的批准。","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126202341,"gmtCreate":1624572722483,"gmtModify":1703840474010,"author":{"id":"3586333932625551","authorId":"3586333932625551","name":"Kenny52041","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586333932625551","idStr":"3586333932625551"},"themes":[],"htmlText":"power~~~~","listText":"power~~~~","text":"power~~~~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126202341","repostId":"1182915557","repostType":4,"isVote":1,"tweetType":1,"viewCount":2333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}